A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

412 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-08

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to assess the overall efficacy of a single intervertebral local administration of AGA111 in patients with degenerative disc disease undergoing lumbar interbody fusion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

NCT05574543

Degenerative Disc Disease

COMPLETED PHASE1/PHASE2

A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo

NCT01771471

Degenerative Disc Disease

TERMINATED PHASE2

Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal Fusion

NCT02205138

Degenerative Disc Disease

COMPLETED PHASE2

Randomized Controlled Clinical Study of Biplanar Ultrasound-guided Puncture of Lumbar Interforamen

NCT06315803

Lumbar Disc Herniation Percutaneous Endoscopic Lumbar Discectomy Three-dimension Ultrasound +1 more

COMPLETED NA

KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion

NCT04294004

Degenerative Disc Disease Spinal Fusion

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single intervertebral local administration of AGA111 in patients with degenerative disc disease undergoing lumbar interbody fusion. About 400 subjects who meet the eligibility criteria will be randomly assigned to the following two treatment groups in a 1:1 ratio.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Degenerative Disc Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AGA111

AGA111 in autologous blood coagulum (ABC) is locally delivered at the intervertebral space.

Group Type EXPERIMENTAL

AGA111

Intervention Type DRUG

AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.

Placebo

Placebo in ABC is locally delivered at the intervertebral space.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AGA111

AGA111 is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.

Intervention Type DRUG

Placebo

Placebo is locally administered in an ABC carrier at the intervertebral space during the lumbar interbody fusion.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Has degenerative disc disease of L3-S1 with low back pain, with or without a history of radiating leg or buttock pain, paresthesia, numbness or weakness secondary to radiculopathy of the corresponding spinal segment;
2. Has radiographic evidence (e.g., X-ray and CT/magnetic resonance imaging MRI) of degenerative disc disease;
3. Adults ≥ 18 and ≤ 80 years of age and skeletally mature at the time of surgery;
4. Plan to undergo a single-level lumbar interbody fusion;
5. Preoperative ODI score ≥ 30;
6. Has not respond to conservative treatment (e.g, bed rest, physical therapy, drugs, local injections, manipulation and other non-surgical treatments) for a period of at least 3 months;
7. Willing and able to comply with the protocol and able to understand and sign the subject's informed consent form (ICF) ;
8. Female subjects of child-bearing potential must agree to use a highly effective method of birth control during the study and for 1 year after the administration of investigational drug, and must have a negative pregnancy test prior to the randomization.

Exclusion Criteria

1. Has undergone other decompression, fusion, and/or other non-fusion spinal surgery at the spinal segment intended to undergo the surgery prior to the screening (except for transforaminal endoscopic discectomy);
2. Known other significant lumbar instability;
3. Lumbar scoliosis \> 30 degrees (evaluated by investigators);
4. Presence of active malignancy or prior history of malignancy;
5. Overt or active infection, either local to surgical space or systemic;
6. Patients with a dual-energy X-ray absorption (DXA) total hip T-score ≤ -3.0;
7. Body weight index (BMI) \<18.5 kg/m2 or BMI \> 35 kg/m2;
8. Have received other treatments affecting fusion surgery, such as radiotherapy near the surgical site;
9. Presence of other co-morbidities of the spine or upper/lower extremities that may affect the investigator's assessment of the lumbosacral nervous system and/or pain;
10. Presence of mental disease or psychiatric condition that interferes with the patient's self-assessment of function, pain, or quality of life;
11. History of progressive osseous heteroplasia or fibrodysplasia ossificans progressiva;
12. Known hypersensitivity or allergy to bone morphogenetic protein (BMP) products or their excipient; and/or instrumentation materials in surgery, e.g., titanium, titanium alloy, cobalt chrome, cobalt chrome alloy, or polyetheretherketone (PEEK);
13. Pregnant or lactating women; or plan to become pregnant within 1 year following the study surgery.
14. Other conditions that, in the opinion of the investigator, would interfere with the subject's ability to comply with the protocol, and other conditions that will make the subject inappropriate for participation in the study as judged by the investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Angitia Medical Director

Role: STUDY_DIRECTOR

Angitia Biopharmaceutics Guangzhou Limited

Locations

Explore where the study is taking place and check the recruitment status at each participating site.